Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals EVP Research Eric Swayze reported an open-market sale of company stock. On June 25, 2026, he sold 10,602 shares of Common Stock at a weighted average price of $79.1824 per share in a transaction coded as an open-market sale.
The sale was executed under a Rule 10b5-1 trading plan adopted on March 6, 2026, indicating it was pre-arranged rather than opportunistic. Following the sale, Swayze directly held 21,759 shares of Ionis Pharmaceuticals common stock, and an additional 318 shares were reported as indirectly owned through his son.
IONS submitted a Form 144 notice reporting a proposed sale of 5,635 shares of Common Stock with an aggregate value of $451,699.00. The filing lists 165,262,556 shares outstanding as of 06/26/2026 and names Stifel Nicolaus & Company as the broker. The notice also records two cash stock option exercises dated 06/26/2026 for 3,866 and 1,769 shares.
IONS submitted a Form 144 proposing the sale of 47,884 shares of Common Stock with an aggregate value of $3,880,807.00. The filing lists 165,262,556 shares outstanding as of 06/26/2026 and names Stifel Nicolaus & Company Inc as broker. The shares trace to prior stock option exercises on 01/02/2020 (26,000 shares) and 01/04/2021 (21,884 shares).
IONS filed a Form 144 notice reporting proposed sales of Common Stock tied to restricted equity awards. The notice lists specific grant dates and share counts for restricted stock: 3,110 (01/15/2022), 1,861 (01/15/2021), 1,956 (01/15/2023), 1,900 (02/23/2023) and 1,775 (02/01/2024).
Ionis Pharmaceuticals announced that the FDA has approved TRYNGOLZA (olezarsen) as the first and only treatment indicated to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG, triglycerides ≥500 mg/dL). The drug is given as a 50 mg or 80 mg once-monthly self-administered autoinjector.
The approval is based on Phase 3 CORE and CORE2 data, where TRYNGOLZA lowered fasting triglycerides by up to 72% versus placebo at six months and sustained reductions at 12 months, reduced acute pancreatitis events by up to 91%, and saw 86% of patients with baseline and 12‑month data reach triglyceride levels below 500 mg/dL. The number needed to treat over one year to prevent one acute pancreatitis episode was 20 in the overall cohort and four in the highest‑risk subgroup. TRYNGOLZA will be available for sHTG in the U.S. in July and represents Ionis’ first independent commercial launch in a prevalent condition.
Ionis Pharmaceuticals EVP and Chief Development Officer Holly B. Kordasiewicz reported an exercise-and-sell transaction in Ionis common stock. On June 12, 2026, she sold a total of 60,846 shares in open-market sales, including 19,842 shares at a weighted average price of $74.0503 per share and 41,004 shares at a weighted average price of $73.0934 per share.
The sales were made under a pre-arranged Rule 10b5-1 Trading Plan adopted on March 13, 2026, meaning the trades were scheduled in advance. On the same date, she exercised non-qualified stock options covering a total of 60,846 shares of common stock at exercise prices of $32.60, $56.78, and $60.89 per share, converting derivative awards into shares that were then largely sold for liquidity.
IONIS PHARMACEUTICALS INC director Spencer R. Berthelsen exercised stock options and sold shares on the same day. He exercised non-qualified stock options covering 8,000 shares of Common Stock at an exercise price of $24.42 per share and then sold 8,000 shares in an open-market transaction at $73.49 per share pursuant to a Rule 10b5-1 Trading Plan adopted on September 12, 2025. After these transactions, he directly owned 156,013 shares of Common Stock. The filing also notes 70 shares of Common Stock held by his daughter, for which he disclaims beneficial ownership.
Reported proposed sale of 8,000 shares by an insider via stock option exercise. The filing shows a stock option exercise to sell 8,000 shares with a transaction date of 06/15/2026. A prior sale listed 8,000 shares on 06/01/2026 for $605,360.00.
IONS submitted a Form 144 notifying a proposed sale of Common Stock. The notice lists equity compensation option-exercise lots of 28,951, 19,895, and 12,000 shares and shows a filing/notice date of 06/12/2026 on Nasdaq.